Skip to main content

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Key Partnership, Declares Dividend

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is collaborating with Cancer Research Horizons in the development of oncology drugs utilizing its proprietary PEDAL(TM) platform. Cancer Research Horizons is the innovation engine at the heart of the world’s largest private funder of cancer research, Cancer Research UK (“CRUK”). The partnership will include using POAI’s PEDAL technology to evaluate Cancer Research Horizons’ preclinical drug inhibitors of glutaminase in evaluate which cancer types and patient populations are more likely to respond to treatment featuring these compounds. An artificial intelligence and machine learning platform, PEDAL makes high-confidence, drug-response predictions that provide for a more informed choice of drug-tumor type combinations for clinical development; the technology also increases the probability of clinical success. “Our collaboration with Cancer Research Horizons represents a fundamental shift in drug discovery that could lead to the accelerated development of cancer therapies using compounds originating from the CRUK network and developed by Cancer Research Horizons in partnership with their global network,” said Predictive Oncology CEO Raymond F. Vennare in the press release. “We now have the ability to impact the most critical stage of early drug discovery in a way that has never been done before.”

In addition, the company has declared a dividend. According to the announcement, the company’s board of directors declared a dividend of one one-thousandth of a share of its newly designated series F preferred stock, par value $0.01 per share, for each outstanding share of the common stock held as of 5 p.m. ET on March 27, 2023; the announcement noted that the shares will be distributed at that same time. The announcement also contained information regarding voting at a meeting of stockholders regarding a reverse stock split.

To view the full press releases, visit and

About Predictive Oncology Inc.

Predictive Oncology, a science-driven company on the leading edge of oncology drug discovery, offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world’s largest privately held biobank of more than 150,000 tumor samples. Predictive Oncology’s solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.